Increased Overall Mortality Even after Risk Reducing Surgery for BRCA-Positive Women in Western Sweden
Abstract
:1. Introduction
2. Materials and Methods
3. Results
3.1. Breast Cancer Incidence
3.2. Ovarian Cancer Incidence
3.3. Overall Mortality
4. Discussion
5. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- Miki, Y.; Swensen, J.; Shattuck-Eidens, D.; Futreal, P.A.; Harshman, K.; Tavtigian, S.; Liu, Q.; Cochran, C.; Bennett, L.M.; Ding, W.; et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994, 266, 66–71. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wooster, R.; Neuhausen, S.L.; Mangion, J.; Quirk, Y.; Ford, D.; Collins, N.; Nguyen, K.; Seal, S.; Tran, T.; Averill, D.; et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 1994, 265, 2088–2090. [Google Scholar] [CrossRef] [PubMed]
- Einbeigi, Z.; Bergman, A.; Kindblom, L.G.; Martinsson, T.; Meis-Kindblom, J.M.; Nordling, M.; Suurküla, M.; Wahlström, J.; Wallgren, A.; Karlsson, P. A founder mutation of the BRCA1 gene in Western Sweden associated with a high incidence of breast and ovarian cancer. Eur. J. Cancer 2001, 37, 1904–1909. [Google Scholar] [CrossRef]
- Bergman, A.; Einbeigi, Z.; Olofsson, U.; Taib, Z.; Wallgren, A.; Karlsson, P.; Wahlström, J.; Martinsson, T.; Nordling, M. The western Swedish BRCA1 founder mutation 3171ins5; a 3.7 cM conserved haplotype of today is a reminiscence of a 1500-year-old mutation. Eur. J. Hum. Genet. 2001, 9, 787–793. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kuchenbaecker, K.B.; Hopper, J.L.; Barnes, D.R.; Phillips, K.A.; Mooij, T.M.; Roos-Blom, M.J.; Jervis, S.; van Leeuwen, F.E.; Milne, R.L.; Andrieu, N.; et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA 2017, 317, 2402–2416. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ludwig, K.K.; Neuner, J.; Butler, A.; Geurts, J.L.; Kong, A.L. Risk reduction and survival benefit of prophylactic surgery in BRCA mutation carriers, a systematic review. Am. J. Surg. 2016, 212, 660–669. [Google Scholar] [CrossRef] [PubMed]
- Casey, M.J.; Synder, C.; Bewtra, C.; Narod, S.A.; Watson, P.; Lynch, H.T. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations. Gynecol. Oncol. 2005, 97, 457–467. [Google Scholar] [CrossRef] [PubMed]
- Finch, A.P.; Lubinski, J.; Møller, P.; Singer, C.F.; Karlan, B.; Senter, L.; Rosen, B.; Maehle, L.; Ghadirian, P.; Cybulski, C.; et al. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J. Clin. Oncol. 2014, 32, 1547–1553. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Domchek, S.M.; Friebel, T.M.; Singer, C.F.; Gareth Evans, D.; Lynch, H.T.; Isaacs, C.; Garber, J.E.; Neuhausen, S.L.; Matloff, E.; Eeles, R.; et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 2010, 304, 967–975. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- van der Velde, N.M.; Mourits, M.J.E.; Arts, H.J.G.; de Vries, J.; Leegte, B.K.; Dijkhuis, G.; Oosterwijk, J.C.; de Bock, G.H. Time to stop ovarian cancer screening in BRCA1/2 mutation carriers? Int. J. Cancer 2009, 124, 919–923. [Google Scholar] [CrossRef] [PubMed]
- Danckert, B.; Ferlay, J.; Engholm, G.; Hansen, H.L.; Johannesen, T.B.; Khan, S.; Køtlum, J.E.; Ólafsdóttir, E.; Schmidt, L.K.H.; Virtanen, A.; et al. NORDCAN: Cancer Incidence, Mortality, Prevalence and Survival in the Nordic Countries, Version 8.2 (26.03.2019). 2019. Available online: http: //www.ancr.nu (accessed on 2 December 2019).
- Working Group Report. International Association of Cancer Registries (IARC). Internal Report No. 2004/02. International rules for multiple primary cancers (ICD-0 third edition). Eur. J. Cancer Prev. 2005, 14, 307–308. [Google Scholar] [CrossRef] [PubMed]
- Stata Statistical Software. Stata Statistical Software. Stata: Release 15 Statistical Software; StataCorp LLC: College Station, TX, USA, 2017. [Google Scholar]
- Mavaddat, N.; Michailidou, K.; Dennis, J.; Lush, M.; Fachal, L.; Lee, A.; Tyrer, J.P.; Chen, T.H.; Wang, Q.; Bolla, M.K.; et al. Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. Am. J. Hum. Genet. 2019, 104, 21–34. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Crum, C.P.; Drapkin, R.; Kindelberger, D.; Medeiros, F.; Miron, A.; Lee, Y. Lessons from BRCA: The tubal fimbria emerges as an origin for pelvic serous cancer. Clin. Med. Res. 2007, 5, 35–44. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Guney Eskiler, G. Talazoparib to treat BRCA-positive breast cancer. Drugs Today Barc. 2019, 55, 459–467. [Google Scholar] [CrossRef] [PubMed]
- Rivera, C.M.; Grossardt, B.R.; Rhodes, D.J.; Brown, R.D., Jr.; Roger, V.L.; Joseph Melton, L., III; Rocca, W.A. Increased cardiovascular mortality after early bilateral oophorectomy. Menopause 2009, 16, 15–23. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gordhandas, S.; Norquist, B.M.; Pennington, K.P.; Yung, R.L.; Laya, M.B.; Swisher, E.M. Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2 mutations; a systematic review of risks and benefits. Gynecol. Oncol. 2019, 153, 192–200. [Google Scholar] [CrossRef] [PubMed]
- Snow, A.; Chen, D.; Lang, J.E. The current status of the clinical utility of liquid biopsies in cancer. Expert Rev. Mol. Diagn. 2019, 19, 1031–1041. [Google Scholar] [CrossRef] [PubMed]
- Clatot, F. Review ctDNA and breast cancer. Recent Results Cancer Res. 2020, 215, 231–252. [Google Scholar] [PubMed]
- Thompson, D.; Easton, D. Variation in BRCA1 cancer risks by mutation position. Cancer Epidemiol Biomark. Prev. 2002, 11, 329–336. [Google Scholar]
- Mersch, J.; Jackson, M.A.; Park, M.; Nebgen, D.; Peterson, S.K.; Singletary, C.; Arun, B.K.; Litton, J.K. Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian. Cancer 2015, 121, 269–275. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Breast cancer in the cohort | |
All women, cancer-free when registered | 253 |
All women cancer-free and with both breasts | 249 |
Breast cancer diagnoses | 31/249 |
Diagnoses during surveillance | 25/31 |
Diagnoses from final pathology report, RRM | 4/31 |
Diagnoses after RRM | 2/31 |
Mean age at diagnosis (range) | 46.0 (32.4–64.4) |
Median age at RRM | 42.3 (22.0–65.3) |
Ovarian cancer in the cohort | |
All women, with ovaries and cancer-free when registered | 239 |
Ovarian cancer diagnosis | 14/239 |
Diagnosis during surveillance | 7/14 |
Diagnosis from final pathology report, RRSO | 4/14 |
Diagnosis after RRSO | 3/14 |
Mean age at diagnosis (range) | 46.7 (39.1–51.5) |
Median age at RRSO | 43.4 (28.2–79.7) |
Breast Cancer Incidence | Follow-Up Time, Years, Median (Range) | Breast Years | Number of Breast Cancers (Expected Number) | SIR (95% CI) |
Women before RRM (n = 249) | 3.85 (0.02–19.9) | 2721.6 | 25 (1.8) | 14.0 (9.42–20.7) |
Women after RRM (n = 184) | 5.3 (0.3–23.8) | 1271.7 | 2 (1.04) | 1.93 (0.48–7.70) |
Ovarian Cancer Incidence | Follow-Up Time, Years, Median (Range) | Person Years | Number of Ovarian Cancers (Expected Number) | SIR (95% CI) |
Women before RRSO (n = 239) | 2.2 (0.0–17.3) | 887.4 | 7 (0.1) | 124.6 (59.4–261.3) |
Women after RRSO (n = 136) | 7.6 (0.58–23.8) | 1883.9 | 3 (0.2) | 13.5 (4.34–41.8) |
Mortality | Follow-Up Time, Tears, Median (Range) | Person Years | Number of Deaths (Expected Number) | SMR (95% CI) |
All women in cohort (n = 253) | 7.6 (0.8–21.1) | 2160.6 | 16 (4.9) | 3.24 (1.99–5.30) |
Women before any risk reducing surgery (n = 235) | 2.1 (0.0–17.7) | 833.6 | 4 (0.7) | 5.56 (2.09–14.8) |
Women after RRM (n = 80) | 5.3 (0.6–19.1) | 577.6 | 4 (1.0) | 4.15 (1.56–11.0) |
Women after RRSO (n = 136) | 7.4 (0.7–21.1) | 1144.3 | 11 (3.7) | 2.99 (1.66–5.40) |
Women after both RRM and RRSO (n = 62) | 6.5 (0.9–19.3) | 480.5 | 4 (0.9) | 4.32 (1.62–11.5) |
Cause of Death in the Cohort | |
---|---|
Breast cancer | 3/16 |
Breast cancer after RRM | 0/3 |
Ovarian cancer | 7/16 |
Peritoneal cancer of ovarian origin after RRSO | 5/7 |
Other cancer | 3/16 |
Other cause, non-malignant | 3/16 |
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Öfverholm, A.; Einbeigi, Z.; Wigermo, A.; Holmberg, E.; Karsson, P. Increased Overall Mortality Even after Risk Reducing Surgery for BRCA-Positive Women in Western Sweden. Genes 2019, 10, 1046. https://doi.org/10.3390/genes10121046
Öfverholm A, Einbeigi Z, Wigermo A, Holmberg E, Karsson P. Increased Overall Mortality Even after Risk Reducing Surgery for BRCA-Positive Women in Western Sweden. Genes. 2019; 10(12):1046. https://doi.org/10.3390/genes10121046
Chicago/Turabian StyleÖfverholm, Anna, Zakaria Einbeigi, Antonia Wigermo, Erik Holmberg, and Per Karsson. 2019. "Increased Overall Mortality Even after Risk Reducing Surgery for BRCA-Positive Women in Western Sweden" Genes 10, no. 12: 1046. https://doi.org/10.3390/genes10121046
APA StyleÖfverholm, A., Einbeigi, Z., Wigermo, A., Holmberg, E., & Karsson, P. (2019). Increased Overall Mortality Even after Risk Reducing Surgery for BRCA-Positive Women in Western Sweden. Genes, 10(12), 1046. https://doi.org/10.3390/genes10121046